Alkalinization
Analgesics..
Antiandrogens..
Bromhexine
Budesonide
Cannabidiol
Colchicine
Conv. Plasma
Curcumin
Ensovibep
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Iota-carragee..
Ivermectin
Lactoferrin
Lifestyle..
Melatonin
Metformin
Molnupiravir
Monoclonals..
Nigella Sativa
Nitazoxanide
Nitric Oxide
Paxlovid
Peg.. Lambda
Povidone-Iod..
Quercetin
Remdesivir
Vitamins..
Zinc

Other
Feedback
Home
Home   COVID-19 treatment studies for Vitamin D  COVID-19 treatment studies for Vitamin D  C19 studies: Vitamin D  Vitamin D   Select treatmentSelect treatmentTreatmentsTreatments
Alkalinization Meta Lactoferrin Meta
Melatonin Meta
Bromhexine Meta Metformin Meta
Budesonide Meta Molnupiravir Meta
Cannabidiol Meta
Colchicine Meta Nigella Sativa Meta
Conv. Plasma Meta Nitazoxanide Meta
Curcumin Meta Nitric Oxide Meta
Ensovibep Meta Paxlovid Meta
Famotidine Meta Peg.. Lambda Meta
Favipiravir Meta Povidone-Iod.. Meta
Fluvoxamine Meta Quercetin Meta
Hydroxychlor.. Meta Remdesivir Meta
Iota-carragee.. Meta
Ivermectin Meta Zinc Meta

Other Treatments Global Adoption
All Studies   Meta Analysis   Recent:  
0 0.5 1 1.5 2+ Mortality 70% Improvement Relative Risk c19early.org/d De Smet et al. Vitamin D for COVID-19 Sufficiency Are vitamin D levels associated with COVID-19 outcomes? Retrospective 186 patients in Belgium Lower mortality with higher vitamin D levels (p=0.015) De Smet et al., American J. Clinical Pathology, doi:10.1093/ajcp/aqaa252 Favors vitamin D Favors control
Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality
De Smet et al., American Journal of Clinical Pathology, doi:10.1093/ajcp/aqaa252
De Smet et al., Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality, American Journal of Clinical Pathology, doi:10.1093/ajcp/aqaa252
Nov 2020   Source   PDF  
  Twitter
  Facebook
Share
  All Studies   Meta
Retrospective 186 hospitalized patients in Belgium showing that 59% of patients were vitamin D deficient, and that non-vitamin D deficient patients had significantly lower mortality risk, RR 0.26, p = 0.015.
risk of death, 70.1% lower, RR 0.30, p = 0.02, high D levels 7 of 77 (9.1%), low D levels 20 of 109 (18.3%), adjusted per study, odds ratio converted to relative risk, >20ng/mL.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
De Smet et al., 25 Nov 2020, retrospective, Belgium, peer-reviewed, 5 authors.
All Studies   Meta Analysis   Submit Updates or Corrections
This PaperVitamin DAll
Abstract: AJCP / Original Article Serum 25(OH)D Level on Hospital Admission Associated With COVID-19 Stage and Mortality Dieter De Smet, MD,1 Kristof De Smet, MD,2 Pauline Herroelen, MSc,1 Stefaan Gryspeerdt, MD,2 and Geert A. Martens, MD, PhD1,3,4, From the 1AZ Delta Medical Laboratories and 2Department of Radiology, AZ Delta General Hospital, Roeselare, Belgium; 3VUB Metabolomics Platform, Brussels Free University, Brussels, Belgium; and 4Department of Biomolecular Medicine, Ghent University, Ghent, Belgium. Am J Clin Pathol March 2021;155:381-388 DOI: 10.1093/AJCP/AQAA252 ABSTRACT Objectives: Vitamin D deficiency was previously correlated with incidence and severity of coronavirus disease 2019 (COVID-19). We investigated the association between serum 25-hydroxyvitamin D (25(OH)D) level on admission and radiologic stage and outcome of COVID-19 pneumonia. Methods: A retrospective observational trial was done on 186 severe acute respiratory syndrome coronavirus 2 (SARSCoV-2)–infected individuals hospitalized from March 1, 2020, to April 7, 2020, with combined chest computed tomography (CT) and 25(OH)D measurement on admission. Multivariate regression analysis was performed to study if vitamin D deficiency (25(OH)D <20 ng/mL) correlates with survival independently of confounding comorbidities. Results: Of the patients with COVID-19, 59% were vitamin D deficient on admission: 47% of females and 67% of males. In particular, male patients with COVID19 showed progressively lower 25(OH)D with advancing radiologic stage, with deficiency rates increasing from 55% in stage 1 to 74% in stage 3. Vitamin D deficiency on admission was not confounded by age, ethnicity, chronic lung disease, coronary artery disease/hypertension, or diabetes and was associated with mortality (odds ratio [OR], 3.87; 95% confidence interval [CI], 1.30-11.55), independent of age (OR, 1.09; 95% CI, 1.03-1.14), chronic lung disease (OR, 3.61; 95% CI, 1.18-11.09), and extent of lung damage expressed by chest CT severity score (OR, 1.12; 95% CI, 1.01-1.25). Conclusions: Low 25(OH)D levels on admission are associated with COVID-19 disease stage and mortality. © American Society for Clinical Pathology, 2020. All rights reserved. For permissions, please e-mail: journals.permissions@oup.com Key Points • A remarkably high fraction (59%) of patients with coronavirus disease 2019 (COVID-19) are vitamin D deficient (25(OH)D <20 ng/mL) on admission. Deficiency was most pronounced in men with advanced radiologic stages of COVID-19 pneumonia. • Vitamin D deficiency on admission was associated with COVID-19 mortality with an odds ratio of 3.87, independent of age, chronic lung disease, coronary artery disease, hypertension, or diabetes. In a subset of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infections, excessive recruitment of proinflammatory cells and cytokine release contribute to alveolar and endothelial damage, triggering a vicious cycle that evolves toward severe coronavirus disease 2019 (COVID-19).1,2 Beside its role in calcium metabolism, 1,25-dihydroxyvitamin D is a pleiotropic regulator of the immune system.3-5 It stimulates the expression of cathelicidins and β-defensins in respiratory epithelia as a barrier to pathogen invasion.6,7 It acts as a protolerogenic and anti-inflammatory cytokine by inhibiting T helper 1 (Th1) proliferation and switching Th1 CD4 T cells and M1-polarized macrophages toward a type II immunity. Vitamin D deficiency (25-hydroxyvitamin D..
Loading..
Please send us corrections, updates, or comments. Vaccines and treatments are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment, vaccine, or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit